Fentanyl has dominated the overdose conversation for years, but the latest drug threats are becoming increasingly difficult to identify by name alone. Synthetic opioids, veterinary sedatives, stimulants, and newly manufactured compounds are appearing in combinations that can produce dangerous and sometimes unpredictable effects.
For people seeking drug rehab, this changing landscape raises an important question: What happens when someone is exposed to multiple substances without even knowing what they have taken?
The rise in polysubstance overdoses reveals a more complicated public health crisis, one that requires closer attention to emerging drug trends, toxicology findings, and how addiction treatment responds to increasingly complex patterns of substance use.
What the Data Reveals About Polysubstance Overdoses
Polysubstance use refers to exposure to two or more drugs, whether intentional or unintentional. This includes combinations such as fentanyl and cocaine, opioids mixed with veterinary sedatives, or counterfeit prescription pills containing multiple synthetic compounds.
According to the Centers for Disease Control and Prevention (CDC), 47% of drug overdose deaths across 37 states and Washington, D.C., in 2023 involved both opioids and stimulants.
Although national overdose deaths declined substantially in 2024, the emergence of new drug combinations presents a separate challenge. Fentanyl remains a major threat, but identifying fentanyl alone no longer provides a complete picture of what someone may have consumed.
New Jersey’s Emerging Medetomidine Overdose Threat
In November 2024, the New Jersey Department of Health issued a public health alert after the New Jersey Poison Control Center identified eight patients with suspected medetomidine exposure between November 11 and November 25.
All eight patients reported heroin use, but their symptoms suggested exposure to an additional substance. Each experienced sedation and an abnormally slow heart rate, while some also developed respiratory depression. Among patients who received naloxone, responses were mixed.
The suspected culprit was medetomidine, a veterinary sedative increasingly identified as an adulterant in the illegal opioid supply. Unlike fentanyl and other opioids, medetomidine does not respond directly to naloxone, creating additional challenges during emergency treatment.
The concern has only grown. In April 2026, the New Jersey Department of Health issued an updated health alert, confirming an increasing presence of medetomidine in the state’s illegal fentanyl and opioid supply. The agency also warned healthcare providers about potentially life-threatening withdrawal complications.
These findings demonstrate that polysubstance exposure is not simply a developing national concern. New Jersey healthcare providers are already encountering cases in which the presence of additional synthetic substances changes how an overdose must be managed.
Emerging Synthetic Drugs Changing the Illegal Drug Supply
Medetomidine is only one example of a much broader development.
The Center for Forensic Science Research and Education (CFSRE) reported discovering 27 new psychoactive substances in 2025. Its forensic testing identified 134 different novel psychoactive substances that year, demonstrating how rapidly drug formulations continue to evolve.
Several substances and drug classes deserve particular attention.
Xylazine (Tranq)
Xylazine is another veterinary sedative increasingly found mixed with fentanyl and other illicit opioids. Often referred to as tranq, it has attracted particular concern because of its association with severe skin wounds, infections, and tissue damage that can develop beyond the injection site.
These complications introduce medical concerns that extend beyond the immediate overdose, sometimes requiring specialized wound care alongside addiction treatment.
Nitazenes and Other Novel Synthetic Opioids
Nitazenes are a class of laboratory-produced opioids, some of which are exceptionally potent. Compounds such as protonitazene and metonitazene have appeared in forensic drug testing.
More recently, researchers have also identified emerging orphine analogues, including N-propionitrile chlorphine, in fatal overdose investigations.
A January 2026 CFSRE alert documented this compound in 25 fatal overdose blood specimens. Some involved the substance alone, while others contained additional opioids, stimulants, or novel benzodiazepines.
Synthetic Benzodiazepines and Stimulants
Bromazolam and phenazolam are examples of novel benzodiazepines identified in the recreational drug market. When combined with opioids, sedative substances can further increase the risk of dangerous central nervous system depression.
Emerging synthetic stimulants, including certain cathinone compounds, add another dimension to the problem.
These are not necessarily entirely new categories of drugs. Rather, manufacturers continue introducing chemical variations and combining existing compounds, making the contents of an unregulated drug product increasingly difficult to anticipate.
Why Polysubstance Overdoses Are More Difficult to Treat
The immediate concern is not simply that multiple drugs are present. Different substances can produce competing symptoms, interact unpredictably, and require different medical interventions.
An individual exposed to fentanyl and cocaine, for example, may experience opioid-related respiratory depression alongside stimulant-related cardiovascular complications. Another person exposed to fentanyl and medetomidine may survive the initial overdose but subsequently experience serious withdrawal complications.
A separate CDC investigation involving 23 patients in Pittsburgh between October 2024 and March 2025 documented severe withdrawal following exposure to illegally manufactured opioids containing medetomidine. Most patients required intensive care-level management. These findings reinforce the importance of comprehensive medical evaluation rather than assuming every suspected opioid overdose will follow the same clinical course.
If an overdose is suspected, call 911 immediately, administer naloxone when available, and follow emergency dispatcher instructions. Naloxone should still be administered when opioid exposure is possible, even if additional non-opioid substances are suspected.
What These Trends Mean for Drug Addiction Treatment
The changing drug supply also has implications beyond emergency departments.
Someone entering drug rehab may have developed physical dependence on substances they never knowingly intended to consume. Consequently, a treatment plan based exclusively on someone’s reported primary drug use may overlook additional withdrawal risks. Effective drug treatment programs must account for substance use history, possible co-occurring dependencies, physical health, and individual recovery needs.
For individuals seeking opioid rehab, medication-assisted treatment for drug addiction remains an important evidence-based option. Medications such as buprenorphine can help manage opioid cravings and withdrawal symptoms. However, these medications do not automatically address dependence on every additional substance, making appropriate clinical assessment and coordinated care essential.
At North Jersey Recovery Center, medication-assisted treatment is integrated with counseling and psychiatric care when clinically appropriate. Individuals requiring medically supervised detoxification can also be connected with accredited partner providers before entering the center’s outpatient programs.
Frequently Asked Questions
Can contaminated drugs cause someone to develop multiple dependencies without realizing it?
Yes. Repeated exposure to certain undisclosed ingredients can result in physical dependence on more than one substance, even when someone consistently purchases what they believe is the same drug. They may not recognize the additional dependence until they stop us,ing and experience withdrawal symptoms they have never encountered before.
Can standard drug tests identify every emerging synthetic drug?
No. Routine drug screening panels may not detect newer synthetic opioids, sedatives, or other emerging compounds. This creates additional risk as a person could test positive for one drug while additional, potentially more dangerous substances remain undetected, creating a misleading picture of the actual exposure.
How does one synthetic drug end up being sold under different street names?
Street names often develop through regional slang, dealer marketing, and changes in how a substance is packaged or sold. As synthetic drugs circulate through different markets, the same compound may acquire several informal names, while distributors may introduce new labels to distinguish their products. Unlike chemical names, street names are not standardized, so terminology can vary considerably between communities.
Recovery Must Account for a Changing Drug Supply
The growing presence of unfamiliar substances in the illegal drug supply makes continued use increasingly difficult to predict. For someone living with addiction, recognizing that risk can be an important reason to seek help now, before another exposure becomes a medical emergency.
North Jersey Recovery Center offers drug rehab and addiction treatment in Fair Lawn, NJ, with programs designed around each individual’s recovery needs. Serving Bergen County and surrounding North Jersey communities, our team is here to help you explore your options and find a path forward.
